Octreotide

Somatostatin analog that may increase the risk of hypoglycemia. Dose adjustment and increased glucose monitoring may be required.

Somatostatin analog may increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.

May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.

Somatostatin analog that may increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.

Somatostatin analog that may increase the risk of hypoglycemia; dose adjustment and increased glucose monitoring required.

Short-acting octreotide competitively binds to somatostatin receptors and may interfere with LUTATHERA efficacy. Discontinue at least 24 hours prior to each LUTATHERA dose.

Concurrent administration of short-acting octreotide significantly decreases systemic exposure of telotristat ethyl and its active metabolite. Administer short-acting octreotide at least 30 minutes after telotristat ethyl.

Dose adjustment of bromocriptine may be necessary when used concomitantly with octreotide.

Concomitant use in acromegalic patients increases bromocriptine plasma levels (AUC increased approximately 38%).

Octreotide decreases cyclosporine bioavailability; dose adjustment of cyclosporine may be necessary.

Octreotide decreases digoxin peak exposure; careful assessment of clinical response is needed due to narrow therapeutic ratio.

Concomitant administration decreases bioavailability of octreotide; may require increased octreotide dose.

May increase glucose-lowering effect of glipizide and susceptibility to hypoglycemia; monitor closely.

May increase risk of hypoglycemia. Dose adjustment and increased glucose monitoring may be required.

Somatostatin analog that may increase risk of hypoglycemia; dosage reductions and increased glucose monitoring may be required.

May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.

Somatostatin analog that may increase the risk of hypoglycemia. Dose reductions and increased frequency of glucose monitoring may be required.

Somatostatin analog that may increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.

Somatostatin analog may increase risk of hypoglycemia. Dose adjustment and increased glucose monitoring may be required.

Somatostatin analog that may increase risk of hypoglycemia; dose adjustment and increased glucose monitoring may be required.

May increase risk of hypoglycemia. Dose reductions and increased glucose monitoring may be required.

Somatostatin analog that may increase risk of hypoglycemia. Dose reductions and increased glucose monitoring may be required.

Octreotide may reduce efficacy of combined oral contraceptives; counsel use of alternative non-hormonal or back-up contraception.

May reduce TSH secretion transiently at doses >100 mcg/day when used with levothyroxine.

Lisinopril: bioavailability may be increased, monitor patient's blood pressure and adjust dose of lisinopril if needed (‎ 7 ). Lisinopril Clinical Impact: Concomitant administration of MYCAPSSA increases lisinopril bioavailability [see Clinical Pharmacology (‎12.3) ] . Intervention: Monitor patient's blood pressure and adjust the dosage of lisinopril if needed.

Somatostatin analogue that may reduce blood-glucose-lowering effect and increase susceptibility to hyperglycemia. Dose increases and increased glucose monitoring may be required.

Octreotide used with quinidine (CYP3A4 substrate with narrow therapeutic index) should be used with caution and increased monitoring.

Somatostatin analog that may increase risk of hypoglycemia. Repaglinide dose reductions and increased glucose monitoring may be required.

Drugs Metabolized by CYP 450 Enzymes Clinical Impact: Limited published data indicate that somatostatin analogs including MYCAPSSA may decrease the metabolic clearance of compounds known to be metabolized by cytochrome P450 enzymes, which may be due to the suppression of GH.